Home > Press > Nanogen Obtains GSA Contract for NanoChip® 400 Platform
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has obtained a United States Government Service Administration (GSA) Schedule contract. The contract, number GS-07F-0283T, applies to the company's NanoChip® 400 microarray instrument and reagents.
Nanogen Obtains GSA Contract for NanoChip® 400 Platform
SAN DIEGO, CA | Posted on April 4th, 2007
The contract enables Nanogen to be listed on an approved GSA Schedule and sell its NanoChip products directly to government agencies such as the National Institutes of Health (NIH), military hospitals and Veteran's Administration (VA) hospitals. Nanogen's inclusion as a GSA Schedule Vendor allows government customers to obtain approved pricing and license terms from a pre-qualified vendor. Government agencies typically have separate GSA and non-GSA budgets, and therefore inclusion as a GSA vendor allows Nanogen broader access to government customers' budgets.
"Securing a GSA Schedule contract for the NanoChip platform is a terrific opportunity for Nanogen, because both current and new customers will be able to expedite future purchases through the GSA ordering process," said David Ludvigson, Nanogen's president and chief operating officer. "Increased efficiency, coupled with the opportunity for immediate implementation, will be the result for customers in the government sector."
The NanoChip® 400 instrument is an automated multiplexing platform that laboratories use to detect genetic sequences. Tests can be performed using reagents supplied by Nanogen, or laboratories can develop a variety of "homebrew" assays. The NanoChip instrument employs Nanogen's core microarray technology, which utilizes patented microfluidics and electronic technology to automate sample handling and detection of results.
Founded in 1949, GSA serves as a centralized procurement and property management agency for the federal government. GSA manages more than one-fourth of the government's total procurement dollars and influences the management of $500 billion in federal assets. More information is available at https://www.gsaadvantage.gov .
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Chief Financial Officer
Porter Novelli Life Sciences
Media & Investor Relations
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015
Real-time observation of bond formation by using femtosecond X-ray liquidography February 26th, 2015
Bruker-Sponsored Sixth AFM BioMed Conference Highlights Increasing Impact of AFM in Biological Applications February 26th, 2015
Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015
United Nanotech Innovations Lists Materials for Trade on INSCX™ Exchange and Appoints Fullerex as Merchant February 17th, 2015
Virginia Tech Purchases Two Bruker Fluorescence Microscope Solutions: High-Speed Instruments Combine to Cover Wide Optical Resolution Range February 10th, 2015
Nano Labs Announces the Opportunity to Submit the POLEC Liquid Cement Product for Test Trials to Be Used in the Construction of the New International Airport of Mexico City (NAICM) February 2nd, 2015
The Original Frameless Shower Doors Installs DFI's FuseCube™ to Offer Hydrophobic Protective Coating as a Standard Feature: First DFI FuseCube™ Installed on the East Coast to Enable Key Differentiator for the Original Frameless Shower Doors January 29th, 2015